Arkansas is currently home to 726 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Trifecta-Heart cfDNA-MMDx Study
NCT04707872
Recruiting
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.
Gender:
All
Ages:
All
Trial Updated:
06/19/2024
Locations: Baptist Health Institute for Research and Innovation, Little Rock, Arkansas
Conditions: Heart Transplant Rejection
Register for Updates
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
NCT04333576
Recruiting
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endomet... Read More
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
06/19/2024
Locations: Applied Research Center of Arkansas /ID# 248494, Little Rock, Arkansas
Conditions: Endometriosis
Register for Updates
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
NCT04180215
Recruiting
This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 & HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: University of Arkansas for Medical Sciences, Cancer Institute, Clinical Trials Office, Fayetteville, Arkansas
Conditions: HPV-Related Squamous Cell Carcinoma
Register for Updates
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT03937154
Recruiting
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/19/2024
Locations: Saint Bernards Medical Center, Jonesboro, Arkansas
Conditions: Chemotherapy-induced Thrombocytopenia
Register for Updates
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
NCT06419608
Recruiting
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2024
Locations: WIRG, Little Rock, Arkansas
Conditions: Major Depressive Disorder
Register for Updates
BHV-7000 Acute Treatment of Bipolar Mania
NCT06419582
Recruiting
The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2024
Locations: Pillar Clinical Research, LLC, Bentonville, Arkansas
Conditions: Bipolar Disorder
Register for Updates
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820
Recruiting
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Arkansas Urology, Little Rock, Arkansas
Conditions: Non-Muscle Invasive Bladder Cancer
Register for Updates
Psilocybin for Major Depressive Disorder (MDD)
NCT06308653
Recruiting
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Preferred Research Partners, Inc., Little Rock, Arkansas
Conditions: Depressive Disorder, Major
Register for Updates
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
NCT06224348
Recruiting
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of inadequate response of topical treatment, on background topical corticosteroid (TCS) and/or topical calcineurin inhibitor (TCI). The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
06/18/2024
Locations: Johnson Dermatology Site Number : 8401076, Fort Smith, Arkansas
Conditions: Dermatitis Atopic
Register for Updates
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764
Recruiting
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Arkansas Urology, Little Rock, Arkansas
Conditions: Non-Muscle Invasive Bladder Neoplasms
Register for Updates
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
NCT06157151
Recruiting
This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer
Register for Updates
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878
Recruiting
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Johnson Dermatology, Fort Smith, Arkansas
Conditions: Plaque Psoriasis
Register for Updates